论文部分内容阅读
86例经病理证实的原发性肺癌以阿霉素联合化疗方案治疗。年龄中位数58岁,KPS>50,为不适于手术的Ⅲ、Ⅳ期或拒作手术的Ⅱ期NSCLC或Ⅱ期SCLC。40例SOLC用环磷酰胺、ADM和长春新醶(CAO)或以异环磷酰胺替代环磷酰胺(IAO).缓解率57.5％。IAO缓解率优于CAO,分别为78.6％和46.2％,内5例因化疗有效获手术切除,内3例手术发现化疗后期别提早,有1例标本内未发现癌细胞,说明阿霉素联合方案可成为SCLC的诱导治疗。另46例NSCLC用丝裂霉素ADM和顺铂(MAP),缓解率41.3％,均为PR,提示也有作为诱导治疗的可能,其疗效达目前NSCLC较好的化疗方案要求。86例用阿霉素联合方案,无1例出现心脏毒副反应,脱发副反应最多,为100％,白细胞下降也较多见,45.3％为Ⅱ°,31.4％为Ⅲ°,下降最低时间为化疗后平均13.4天(6—22天),平均19.6天恢复(14—26天)。
86 cases of pathologically confirmed primary lung cancer were treated with doxorubicin combined with chemotherapy. The median age of 58 years, KPS> 50, stage III, IV or operative rejection of stage II NSCLC or stage II SCLC. In 40 cases of SOLC, cyclophosphamide, ADM, and Vincristine (CAO) or ifosfamide was substituted for cyclophosphamide (IAO). The remission rate was 57.5%. The remission rate of IAO was better than that of CAO, which was 78.6% and 46.2%, respectively. 5 cases were effectively resected due to chemotherapy, 3 cases were found earlier after chemotherapy, and 1 case had no cancer cells in the sample, indicating that the combination of adriamycin. The protocol can be an induction therapy for SCLC. Another 46 NSCLC with mitomycin ADM and cisplatin (MAP), the remission rate was 41.3%, both PR, suggesting that there may be as an induction therapy, the efficacy of the current NSCLC better chemotherapy program requirements. 86 patients with adriamycin combined regimen, no case of cardiac toxicity side effects, alopecia side effects were the most, for 100%, leukopenia was also more common, 45.3% for the II °, 31.4% for the III °, the minimum time for the decline After chemotherapy, they averaged 13.4 days (6-22 days) and recovered on average 19.6 days (14-26 days).